Chronic lymhocytic leukemia -CLL
Non - Hodgkin lymphoma - NHL

Most frequent adverse reactions  were predominently
hypersensitivity 2% and pyrexia 1%

CNS -
Asthenia  7%  Chills 5%  Fatigue 8%

Dermatologic -
Pruritus  4%  Rash  6%

GI -
Diarrhea  8%   Nausea 18%  Vomiting  14% 

Metabolic /Nutrional -
Hyperurenia     5%    weight reduced  5%

Respiratory -
Cough   3%  Nasopharyngitis  5%

Miscellaneous -
Herpes simplex   2%  Hypersensitivity  4%   Infection 5%  Pyrexia 21%

Known hypersensitivity

Special Precatuions/ warnings-

Mylosuppressants - patients treated  with bendamustine are likely to experience mylosuppression

Infections- infections including pneumonia ans sepsis has been reported during clinical trials. Advice patients to consult doctor in case of signs of infection

Infusion reactions and anaphylaxis - infusion reactions to bendamustine have occurred in clincal trials. Consider disconitinuation in patients  with infusion reactions

Skin reactions- a number of skin reactions have been reported in clinical trials.

Renal function impairment -   bendamustine with caution in patients with mild or moderate renal function impairment

Pregnancy - if this drug is taken during pregnancy or if the patient becomes pregnant  while
taking the drug, appraise the patient the potential hazard to the fetus.

Lactation- decide whether to discontinue nursing or the drug depending upon imporatance
 of the drug to mother.

Children- safety and efficacy of the drug in children have not been established. 

Chronic lymhocytic leukemia -CLL
Non - Hodgkin lymphoma - NHL

Dosage-
Usual dosage-  100mg.m2 administered intravenously IV over 30 minutes on day 1 and 2
of a 28 day cycle upto 6 cycles.

Store at upto 25 C (77F )

1. Inform patients of the possibility of a mild or serious allergic reactions and  advuce them
to immediately report rash, facial swelling, or  difficulty in breathing during or soon after infusion.

2. Inform patients that bendamustine may cause a decrease in WBC, platelets, and red blood cells. This will need frequent monitoring of these parameters.

3. Inform patients to report shortness of breath, significant fatigue, fever or other signs of infection.

4. Bandamustine may cause fetal harm. Advice women not to be become pregnant throughout treatment and for 3 months after Bendamustine therapy is stopped. Advice patients to use  reliable contraceptives for the same period.

5. Advice patients to avoid breast feeding while receiving Bendamustine.

6. Advice patients that Bendamustine may cause tiredness and to avoid driving or operate any  dangerous tools or machinery if they experience this adverse reaction.

7. Advice patients that Bendamustine may cause nausea or vomiting. Instruct patients to report  the same to the doctor if the adverse reaction is severe.

8. Advice patients that Bendamustine may cause diarrhea. If the adverse reaction turns serious  they should report to the doctor.

9. Advice patients that a mild rash or itching occur during treatment with Bendamustine. Advice  them to report  immediately to their doctor.